Singapore - English - HSA (Health Sciences Authority)

siemens healthcare pte. ltd. - immunology - the atellica® im br 27.29 (br) assay is for in vitro diagnostic use in the quantitative serial determination of cancer antigen ca 27.29 in human serum and plasma (edta) using the atellica® im analyzer. the test is intended for use as an aid in monitoring patients previously treated for stage ii or stage iii breast cancer. serial testing for ca 27.29 in the serum and plasma of patients who are clinically free of disease should be used in conjunction with other clinical methods used for the early detection of cancer recurrence. the test is also intended for use as an aid in the management of breast cancer patients with metastatic disease by monitoring the progression or regression of disease in response to treatment

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

br pharmaceuticals ltd - nicotinamide; riboflavin; thiamine hydrochloride - oral tablet - 15mg ; 1mg ; 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

br pharmaceuticals ltd - pyridoxine hydrochloride - oral tablet - 10mg

United States - English - NLM (National Library of Medicine)

br - titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51) - titanium dioxide 2.8 g in 40 g - purpose: sunscreen

United States - English - NLM (National Library of Medicine)

br - titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51) - titanium dioxide 2.8 g in 40 g - purpose: sunscreen

Singapore - English - HSA (Health Sciences Authority)

premier diagnostics pte. ltd. - general hospital - br-5200 / br-5200p is a hassle-free intelligent bilirubin meter. this is an in vitro diagnostic instrument intended to use as an aid in the diagnosis of neonatal jaundice in neonates and for professional in-vitro diagnostic use only

New Zealand - English - Medsafe (Medicines Safety Authority)

link pharmaceuticals ltd - methylnaltrexone bromide 12mg (12mg in 0.6ml) - solution for injection - 12 mg/0.6ml - active: methylnaltrexone bromide 12mg (12mg in 0.6ml) excipient: glycine hydrochloric acid sodium calcium edetate sodium chloride sodium hydroxide water for injection - relistor is indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care when response to laxative therapy has not been sufficient.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

martindale pharmaceuticals ltd - morphine sulfate - solution for infusion - 2mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

martindale pharmaceuticals ltd - morphine sulfate - solution for infusion - 1mg/1ml

Israel - English - Ministry of Health

rafa laboratories ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 25 mg/vial - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.